Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002082 · ClinicalTrials.gov registry record · NA
Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study
A NA study of HIV Infections and Cryptosporidiosis, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 4
- Study locations
NCT00002082 is a NA study of HIV Infections and Cryptosporidiosis that has completed, run by Pfizer. The trial reports 4 study locations across 3 states.
The verdict
NCT00002082, a NA study of HIV Infections and Cryptosporidiosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 4
- Study locations
Study Summary
To evaluate the safety and efficacy of azithromycin in the treatment of intestinal cryptosporidial infection in AIDS patients.
Conditions Studied
Interventions
- DRUG Azithromycin
Study Locations (4)
California
- Infectious Disease Med Group - Oakland
- UCSD Med Ctr - San Diego
New York
- Cornell Univ Med Ctr - New York
Tennessee
- Univ of Tennessee - Memphis
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002082
The ClinicalTrials.gov registry entry for NCT00002082 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.
NCT00002082 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00002082 about?
NCT00002082 is a clinical study titled "Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study". To evaluate the safety and efficacy of azithromycin in the treatment of intestinal cryptosporidial infection in AIDS patients.
What is the current status of trial NCT00002082?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002082 study?
This clinical trial studies the following conditions: HIV Infections, Cryptosporidiosis.
What interventions are being tested in trial NCT00002082?
The interventions under investigation include: Azithromycin (DRUG).
Who is sponsoring clinical trial NCT00002082?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002082 being conducted?
This trial has 4 study locations across California, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.